News

G2G Wants Your Input to Contribute to New ARPA-H Initiative

The White House Office of Science & Technology Policy (OSTP) is establishing the framework for the Advanced Research Projects Agency-Health (ARPA-H) that was included in President Biden’s FY2022 budget. Modeled after the Defense Advanced Research Projects Agency (DARPA), ARPA-H would tackle bold challenges requiring large-scale, cross-sector coordination, employing a non-traditional and nimble approach to high-risk research. Specifically, under Director Eric Lander, PhD from the Broad Institute and MIT who was sworn in as the first Cabinet level Director of OSTP on June 2, 2021, ARPA-H will advance translational science and drive transformational health innovations that tackle gaps in the system and implement health breakthroughs.

G2G is participating in efforts to contribute input to help shape how ARPA-H will function and we would love to hear your thoughts and questions you would like us to address as we continue our dialogue with the OSTP and ARPA-H leadership.

Click here to provide G2G with your feedback.

Recent News

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who

01/27/2025

Haleon Expands Richmond Research and Development Facility

Governor Glenn Youngkin announced today that Haleon, a leading global consumer health company, will invest $54.2 million to upgrade its research & development facility in the City of Richmond. The modernization will enable the company to accommodate innovative technologies and expand its research capabilities. Governor Youngkin met with Haleon leadership in London in July 2024